Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Payables (2016 - 2026)

Tenax Therapeutics' Payables history spans 6 years, with the latest figure at $611861.0 for Q4 2017.

  • On a quarterly basis, Payables fell 15.91% to $611861.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $611861.0, a 15.91% decrease, with the full-year FY2017 number at $611861.0, down 15.91% from a year prior.
  • Payables hit $611861.0 in Q4 2017 for Tenax Therapeutics, up from $579386.0 in the prior quarter.
  • Over the last five years, Payables for TENX hit a ceiling of $1.5 million in Q2 2016 and a floor of $434195.0 in Q2 2017.
  • Historically, Payables has averaged $958556.4 across 4 years, with a median of $939409.5 in 2013.
  • Biggest five-year swings in Payables: soared 70.81% in 2013 and later plummeted 71.46% in 2017.
  • Tracing TENX's Payables over 4 years: stood at $1.0 million in 2013, then fell by 6.01% to $972483.0 in 2015, then dropped by 25.18% to $727599.0 in 2016, then decreased by 15.91% to $611861.0 in 2017.
  • Business Quant data shows Payables for TENX at $611861.0 in Q4 2017, $579386.0 in Q3 2017, and $434195.0 in Q2 2017.